

# Synthesis of Oligosaccharides Resembling the *Streptococcus suis* Serotype 18 Capsular Polysaccharide as a Basis for Glycoconjugate Vaccine Development

Rajat Kumar Singh, Julinton Sianturi, and Peter H. Seeberger\*



Cite This: *Org. Lett.* 2022, 24, 2371–2375



Read Online

ACCESS |



Metrics & More




Article Recommendations



Supporting Information

**ABSTRACT:** Here we report the first total synthesis of several oligosaccharides resembling the capsular polysaccharide of swine pathogen *S. suis* serotype 18 repeating unit  $[\rightarrow 3)\text{-D-GalNAc}(\alpha 1\text{-}3)[\text{D-Glc}(\beta 1\text{-}2)]\text{-D-GalA4OAc}(\beta 1\text{-}3)\text{-D-GalNAc}(\alpha 1\text{-}3)\text{-D-BacNAc4NAC}(\alpha 1\text{-}\rightarrow)_n$ . Access to the pentasaccharide repeating unit antigen proved to be very challenging due to the poor reactivity in the context of the trisaccharide. The challenge was overcome by the creation of a galacturonic acid in a late stage of the synthesis.



*Streptococcus suis* (*S. suis*) infections of farmed pigs cause serious economic losses, and humans have been increasingly infected by these antibiotic-resistant bacteria.<sup>1–3</sup> Capsular polysaccharides (CPSs) surrounding Gram-negative bacteria are the basis of very successful glycoconjugate vaccines against the human pathogen *Streptococcus pneumoniae*. The vaccination of pigs and humans against *S. suis* to prevent rather than treat the disease would avoid the use of antibiotics and reduce the development of antibiotic resistance. Thirty-five *S. suis* serotypes can be distinguished based on their CPS structures. A glycoconjugate vaccine candidate against *S. suis* serotype 2 (SS2) based on isolated CPS<sup>4</sup> and semisynthetic glycoconjugate vaccine candidates for SS2, SS3, SS9, and SS14 have been evaluated.<sup>4,5</sup> The *S. suis* serotype 18 CPS pentasaccharide repeating unit provides an interesting challenge for synthetic chemists as a first step toward a glycoconjugate vaccine for this serotype. The SS18 pentasaccharide repeating unit made up of  $[\rightarrow 3)\text{-D-GalNAc}(\alpha 1\text{-}3)[\text{D-Glc}(\beta 1\text{-}2)]\text{-D-GalA4OAc}(\beta 1\text{-}3)\text{-D-GalNAc}(\alpha 1\text{-}3)\text{-D-BacNAc4NAC}(\alpha 1\text{-}\rightarrow)_n$  (Figure 1a)<sup>6</sup> requires the installation of a 1,2-*cis* linkage between D-bacillosamine and the reducing-end linker. The central galacturonic acid branching unit is a challenge concerning the poor reactivity and protecting group orthogonality.


The SS18 pentasaccharide repeating unit (Figure 1a) contains the rare deoxy amino sugar D-bacillosamine in addition to D-galactosamine, D-galacturonic acid, D-glucose, and D-galactose. A linear approach will require the synthesis of the rare sugar D-bacillosamine derivative building block and the stereocontrolled 1,2-*cis* linkage between the D-bacillosamine derivative and the linker subsequently used for conjugation. The central galacturonic acid will have to be glycosylated twice at the C2 and C3 positions. The presence of C4-OAc at the D-


galacturonic acid of pentasaccharide 1 complicates the synthesis by not allowing the use of most ester protecting groups. Target pentasaccharides 1 and oligosaccharides 2–5 resembling different portions of the CPS repeating unit can be prepared using a linear synthesis strategy with five building blocks 6–10 (Figure 1b).

D-Bacillosamine derivative 6 (Scheme 1) was synthesized starting from D-galactosamine building block 7 and was used to glycosylate the protected reducing end linker 11 using NIS/TMSOTf as a promoter to afford the exclusively  $\alpha$ -linked glycoside 12 in 68% yield. The bulky alkyl substituents of the 4,6-O-silylidene group prevent the attack of the nucleophile from the  $\beta$ -face of the donor, combined with through-space electron donation that stabilizes the oxocarbenium-like intermediate<sup>8</sup> to ensure the complete stereoselectivity of the glycosylation. Silylidene removal using HF in pyridine<sup>9</sup> yielded dihydroxy galactosamine derivative 13 (96%) followed by tosylation of the primary C6 hydroxyl<sup>10</sup> to give 14 in 95% yield. C6-Deoxygenation was achieved via iodination with NaI in refluxing acetone (93% yield of 15), and subsequent dehalogenation/reduction with tributyltin hydride yielded fucosamine<sup>11</sup> derivative 16 (76%). Selective acylation of the amine in 16 using trichloroacetyl chloride<sup>12</sup> afforded 17 in 85% yield. The triflation of 17 using triflic anhydride followed by

Received: February 21, 2022


Published: March 21, 2022





**Figure 1.** (a) Repeating unit of the *S. suis* serotype 18 CPS. (b) Retrosynthetic analysis of target oligosaccharides 1–5.

### Scheme 1. Synthesis of D-Bacillosamine Derivative Acceptor 6




C4 inversion with stoichiometric amounts of sodium azide provided D-bacillosamine derivative **18** in 68% yield over two steps. Oxidative cleavage of the naphthyl ether ( $\text{Nap}$ ) by 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) afforded D-bacillosamine derivative **14** building block **6** in 90% yield.

Galacturonic acid building block **8** was prepared from differentially protected galactose thioglycoside **19** (Scheme 2).<sup>15</sup> Levulinoylation, followed by benzylidene acetal hydrolysis,<sup>16</sup> gave dihydroxy galactose thioglycoside **21**. Selective oxidation of the primary C6 alcohol to the carboxylic acid<sup>17</sup> using TEMPO and subsequent benzylation followed by acetylation gave rise to D-galacturonic acid thioglycoside **8** in 68% yield over three steps. Glucose building block **9** was synthesized in one step from a known thioglycoside **S1**.<sup>18</sup> (See the Supporting Information.)

The oligosaccharide assembly commenced with the NIS/TMSOTf-promoted union of D-bacillosamine derivative **6** and


### Scheme 2. Synthesis of Differentially Protected Galacturonic Acid Building Block 8




D-galactosamine **7**. Removal of the silyl ether group by treatment with HF-Py followed by benzylation gave the differentially protected disaccharide **24** (Scheme 3). Oxidative removal of the naphthyl ether using DDQ furnished disaccharide acceptor **25** in 85% yield. The glycosylation of disaccharide **25** using galacturonic acid **8** afforded the protected trisaccharide. The subsequent cleavage of the silyl ether using HF-Py proved difficult and furnished a complex mixture of products. Desilylation using  $\text{BF}_3 \cdot \text{Et}_2\text{O}$  was successful and produced the desired acceptor **19** **26** in 56% yield over two steps. Several attempts to synthesize tetrasaccharide **28** by the glycosylation of trisaccharide acceptor **26** using selenoglycoside **10** and the corresponding trichloroacetimidate **27**<sup>20,21</sup> were not met with success. The poor nucleophilicity of the free hydroxyl group of **26** is a result of the electron-withdrawing groups at C4 and C6, which rendered glycosylations doomed to failure.

A less direct method using galactose in place of galacturonic acid had to be explored to overcome the reactivity problems associated with the low nucleophilicity of the central galacturonic acid unit. The glycosylation of disaccharide **25** with galactose building block **20** afforded trisaccharide **29** in 94% yield, which was liberated from the silyl ether protective group to furnish trisaccharide acceptor **30**. The union of trisaccharide **30** and selenoglycoside **10** followed by the cleavage of the levulinoyl ester using hydrazine acetate afforded

## Scheme 3. Attempted Synthesis of Tetrasaccharide 28




## Scheme 4. Synthesis of Unprotected Pentasaccharides 1 and 2



tetrasaccharide **32**. The glycosylation of acceptor **32** with glucosamine building block **9** produced pentasaccharide **33** in 64% yield. The central galacturonic acid moiety was prepared by the camphorsulfonic acid (CSA)-mediated hydrolysis of the benzylidene acetal followed by BAIB/TEMPO oxidation, and the selective benzylation of carboxylic acid afforded pentasaccharide **35**. The azide of pentasaccharide **35** was converted into the corresponding acetamide using zinc powder in a THF/Ac<sub>2</sub>O/AcOH mixture; subsequently, silylidene ether and the levulinoyl ester group were deprotected, and the hydrogenation reaction provided the *S. suis* serotype 18 CPS resembling the repeating unit pentasaccharide target **2** in 11% yield over four steps. In addition, pentasaccharide **35** was acetylated followed by azide conversion to acetamide, and the subsequent removal of silylidene and levulinoyl ester and the hydrogenation reaction provided the *S. suis* serotype 18 CPS repeating unit pentasaccharide target **1** in 15% yield over five steps<sup>22</sup> (Scheme 4).

Three oligosaccharides (**3**, **4**, and **5**) that will be essential for subsequent immunological studies to identify the minimally

protective glycan epitope were prepared using a divergent synthesis approach (Scheme 5). The benzylation of galactosamine diol **13** afforded **36** (see the Supporting Information), which was freed from the Nap ether to provide **37**. The glycosylation of monosaccharide **37** with galacturonic acid building block **8** exclusively furnished the  $\beta$ -isomer of disaccharide **38** in 75% yield. Levulinoyl ester cleavage using hydrazine acetate afforded **39**; then, glycosylation with **9** in the presence of TfOH and *N*-iodosuccinimide (NIS) at  $-20$  °C produced trisaccharide **40** in 68% yield. The cleavage of levulinoyl ester and *tert*-butyldimethylsilyl (TBS) ether afforded diol **41**. Conversion of the azide to the corresponding acetamide using Zn/AcOH/Ac<sub>2</sub>O followed by hydrogenation afforded trisaccharide **3** (46% yield over two steps). Trisaccharide **4** was prepared by the TBS removal of **38** in preparation for glycosylation with **10** to furnish trisaccharide **43**. The global deprotection of **43** produced the desired trisaccharide **4**. Disaccharide **5** was readily accessible by deprotection of disaccharide **39** in 46% yield over three steps.

Scheme 5. Synthesis of Oligosaccharides Resembling *S. suis* Serotype 18

In conclusion, we report the total synthesis of several oligosaccharides resembling the CPS of swine pathogen *S. suis* serotype 18 that are the basis for immunological studies and the development of a glycoconjugate vaccine. The rare D-bacillosamine derivative was prepared from D-galactosamine using tin-mediated reduction and dehalogenation. Access to the pentasaccharide repeating unit antigen proved to be very challenging due to the poor reactivity of the trisaccharide intermediate. The challenge was overcome by the creation of galacturonic acid in a late stage of the synthesis. The conjugation-ready glycans prepared using the total synthesis approach will be used for immunological studies.

## ASSOCIATED CONTENT

### Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acs.orglett.2c00596>.

Complete experimental procedures and NMR spectra of synthetic compounds (PDF)

## AUTHOR INFORMATION

### Corresponding Author

**Peter H. Seeberger** – Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, 14476 Potsdam, Germany; Institute of Chemistry and Biochemistry, Freie Universität Berlin, 14195 Berlin, Germany; [orcid.org/0000-0003-3394-8466](https://orcid.org/0000-0003-3394-8466); Email: [peter.seeberger@mpikg.mpg.de](mailto:peter.seeberger@mpikg.mpg.de)

### Authors

**Rajat Kumar Singh** – Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, 14476

Potsdam, Germany; Institute of Chemistry and Biochemistry, Freie Universität Berlin, 14195 Berlin, Germany  
**Julinton Sianturi** – Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, 14476 Potsdam, Germany

Complete contact information is available at: <https://pubs.acs.org/doi/10.1021/acs.orglett.2c00596>

## Funding

Open access funded by Max Planck Society.

## Notes

The authors declare no competing financial interest.

## ACKNOWLEDGMENTS

We acknowledge generous funding by the Max-Planck Society. Open access funding was enabled and organized by Project DEAL.

## REFERENCES

- (1) Feng, Y.; Zhang, H.; Wu, Z.; Wang, S.; Cao, M.; Hu, D.; Wang, C. *Streptococcus suis* infection. *Virulence* **2014**, *5*, 477–497.
- (2) (a) Lun, Z.-R.; Wang, Q.-P.; Chen, X.-G.; Li, A.-X.; Zhu, X.-Q. *Streptococcus suis*: an emerging zoonotic pathogen. *Lancet Infect. Dis.* **2007**, *7*, 201–209. (b) Oberli, M. A.; Tamborini, M.; Tsai, Y.-H.; Werz, D. B.; Horlacher, T.; Adibekian, A.; Gauss, D.; Möller, H. M.; Pluschke, G.; Seeberger, P. H. Molecular Analysis of Carbohydrate–Antibody Interactions: Case Study Using a Bacillus anthracis Tetrasaccharide. *J. Am. Chem. Soc.* **2010**, *132*, 10239–10241.
- (3) Hernandez-Garcia, J.; Wang, J.; Restif, O.; Holmes, M. A.; Mather, A. E.; Weinert, L. A.; Wileman, T. M.; Thomson, J. R.; Langford, P. R.; Wren, B. W.; Rycroft, A.; Maskell, D. J.; Tucker, A. W. Patterns of antimicrobial resistance in *Streptococcus suis* isolates from pigs with or without streptococcal disease in England between 2009 and 2014. *Vet. Microbiol.* **2017**, *207*, 117–124.

- (4) Arends, J. P.; Zanen, H. C. Meningitis Caused by *Streptococcus suis* in Humans. *Rev. Infect. Dis.* **1988**, *10*, 131–137.
- (5) Zhang, S.; Sella, M.; Sianturi, J.; Priegue, P.; Shen, D.; Seeberger, P. H. Discovery of Oligosaccharide Antigens for Semi-Synthetic Glycoconjugate Vaccine Leads against *Streptococcus suis* Serotypes 2, 3, 9 and 14\*\*. *Angew. Chem., Int. Ed.* **2021**, *60*, 14679–14692.
- (6) Corsaut, L.; Martelet, L.; Goyette-Desjardins, G.; Beauchamp, G.; Denicourt, M.; Gottschalk, M.; Segura, M. Immunogenicity study of a *Streptococcus suis* autogenous vaccine in preparturient sows and evaluation of passive maternal immunity in piglets. *BMC Vet. Res.* **2021**, *17*, 72.
- (7) van der Es, D.; Groenia, N. A.; Laverde, D.; Overkleeft, H. S.; Huebner, J.; van der Marel, G. A.; Codee, J. D.C. Synthesis of E. faecium wall teichoic acid fragments. *Bioorg. Med. Chem.* **2016**, *24*, 3893–3907.
- (8) Jeanneret, R. A.; Johnson, S. E.; Galan, M. C. Conformationally Constrained Glycosyl Donors as Tools to Control Glycosylation Outcomes. *J. Org. Chem.* **2020**, *85*, 15801.
- (9) Hagen, B.; van Dijk, J. H. M.; Zhang, Q.; Overkleeft, H. S.; van der Marel, G. A.; Codée, J. D. C. Synthesis of the *Staphylococcus aureus* Strain M Capsular Polysaccharide Repeating Unit. *Org. Lett.* **2017**, *19*, 2514–2517.
- (10) Mizuno, M.; Matsumoto, H.; Goto, K.; Hamasaki, K. Synthesis of aminoglycoside derivatives on a Cbz-type heavy fluorine tag. *Tetrahedron Lett.* **2006**, *47*, 8831–8835.
- (11) Cheng, J. M. H.; Dangerfield, E. M.; Timmer, M. S. M.; Stocker, B. L. A divergent approach to the synthesis of iGb3 sugar and lipid analogues via a lactosyl 2-azido-sphingosine intermediate. *Org. Biomol. Chem.* **2014**, *12*, 2729–2736.
- (12) van Mechelen, J.; Voorneveld, J.; Overkleeft, H. S.; Filippov, D. V.; van der Marel, G. A.; Codée, J. D. C. Synthesis of orthogonally protected and functionalized bacillosamines. *Org. Biomol. Chem.* **2020**, *18*, 2834–2837.
- (13) Emmadi, M.; Kulkarni, S. S. Synthesis of orthogonally protected bacterial, rare-sugar and D -glycosamine building blocks. *Nat. Protoc.* **2013**, *8*, 1870–1889.
- (14) Lloyd, D.; Bylsma, M.; Bright, D. K.; Chen, X.; Bennett, C. S. Mild Method for 2-Naphthylmethyl Ether Protecting Group Removal Using a Combination of 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) and  $\beta$ -Pinene. *J. Org. Chem.* **2017**, *82*, 3926–3934.
- (15) Shibata, T. K.; Matsumura, F.; Wang, P.; Yu, S.; Chou, C.-C.; Khoo, K.-H.; Kitayama, K.; Akama, T. O.; Sugihara, K.; Kanayama, N.; Kojima-Aikawa, K.; Seeberger, P. H.; Fukuda, M.; Suzuki, A.; Aoki, D.; Fukuda, M. N. Identification of Mono- and Disulfated N-Acetyl-lactosaminyl Oligosaccharide Structures as Epitopes Specifically Recognized by Humanized Monoclonal Antibody HMOCC-1 Raised against Ovarian Cancer. *J. Biol. Chem.* **2012**, *287*, 6592–6602.
- (16) Sankaranarayanan, N. V.; Strebler, T. R.; Boothello, R. S.; Sheerin, K.; Raghuraman, A.; Sallas, F.; Mosier, P. D.; Watermeyer, N. D.; Oscarson, S.; Desai, U. R. A Hexasaccharide Containing Rare 2-O-Sulfate-Glucuronic Acid Residues Selectively Activates Heparin Cofactor II. *Angew. Chem., Int. Ed.* **2017**, *56*, 2312–2317.
- (17) Parameswarappa, S. G.; Reppe, K.; Geissner, A.; Ménová, P.; Govindan, S.; Calow, A. D. J.; Wahlbrink, A.; Weishaupt, M. W.; Monnanda, B. P.; Bell, R. L.; Pirofski, L. A.; Suttorp, N.; Sander, L. E.; Witzentrath, M.; Pereira, C. L.; Anish, C.; Seeberger, P. H. A Semi-synthetic Oligosaccharide Conjugate Vaccine Candidate Confers Protection against *Streptococcus pneumoniae* Serotype 3 Infection. *Cell Chem. Biol.* **2016**, *23*, 1407–1416.
- (18) Mishra, R.; Elgland, M.; Begum, A.; Fyrner, T.; Konradsson, P.; Nystrom, S.; Hammarstrom, P. Impact of N-glycosylation site variants during human PrP aggregation and fibril nucleation. *Biochim Biophys Acta Proteins Proteom.* **2019**, *1867*, 909–921.
- (19) Kelly, D. R.; Roberts, S. M.; Newton, R. F. The Cleavage of t-Butyldimethylsilyl Ethers with Boron Trifluoride Etherate. *Synth. Commun.* **1979**, *9*, 295–299.
- (20) Das, R.; Mukhopadhyay, B. Chemical O-Glycosylations: An Overview. *ChemistryOpen* **2016**, *5*, 401–433.
- (21) Behera, A.; Rai, D.; Kulkarni, S. S. Total Syntheses of Conjugation-Ready Trisaccharide Repeating Units of *Pseudomonas aeruginosa* O11 and *Staphylococcus aureus* Type 5 Capsular Polysaccharide for Vaccine Development. *J. Am. Chem. Soc.* **2020**, *142*, 456–467.
- (22) Qin, C.; Schumann, B.; Zou, X.; Pereira, C. L.; Tian, G.; Hu, J.; Seeberger, P. H.; Yin, J. Total Synthesis of a Densely Functionalized *Plesiomonas shigelloides* Serotype 51 Aminoglycoside Trisaccharide Antigen. *J. Am. Chem. Soc.* **2018**, *140*, 3120–3127.